Adicet Bio, Inc. (ACET) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Adicet Bio, Inc. (ACET) Bundle
Explore Adicet Bio, Inc. (ACET) financial outlook with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to determine Adicet Bio, Inc. (ACET) intrinsic value and refine your investment approach.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.0 | 17.9 | 9.7 | 25.0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 1699.3 | -45.65 | 156.83 | -100 | 13.59 | 13.59 | 13.59 | 13.59 | 13.59 |
EBITDA | -26.9 | -37.4 | -60.4 | -64.7 | -136.5 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | -2701.61 | -208.95 | -620.86 | -258.91 | 100 | -60 | -60 | -60 | -60 | -60 |
Depreciation | 1.2 | 2.0 | 4.1 | 5.0 | 6.1 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 124.42 | 10.9 | 41.8 | 20.04 | 100 | 54.55 | 54.55 | 54.55 | 54.55 | 54.55 |
EBIT | -28.1 | -39.4 | -64.5 | -69.7 | -142.6 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | -2826.03 | -219.85 | -662.66 | -278.95 | 100 | -60 | -60 | -60 | -60 | -60 |
Total Cash | 62.4 | 94.6 | 277.5 | 257.7 | 159.7 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .9 | .0 | .2 | .4 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 93.97 | 0 | 2.2 | 1.74 | 100 | 39.58 | 39.58 | 39.58 | 39.58 | 39.58 |
Inventories | .7 | -3.1 | 4.7 | 2.6 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 67.54 | -17.28 | 48.08 | 10.27 | 100 | 41.72 | 41.72 | 41.72 | 41.72 | 41.72 |
Accounts Payable | 1.1 | 1.6 | 3.3 | 4.4 | 2.6 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 105.73 | 8.67 | 33.54 | 17.62 | 100 | 51.97 | 51.97 | 51.97 | 51.97 | 51.97 |
Capital Expenditure | -1.1 | -1.0 | -13.0 | -16.8 | -4.5 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | -107.54 | -5.53 | -134.08 | -67.15 | 100 | -54.54 | -54.54 | -54.54 | -54.54 | -54.54 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -28.1 | -36.6 | -64.3 | -67.0 | -142.6 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -28.5 | -30.4 | -79.6 | -75.7 | -139.8 | -2.6 | .0 | .0 | .0 | .0 |
WACC, % | 9.7 | 9.6 | 9.7 | 9.64 | 9.7 | 9.67 | 9.67 | 9.67 | 9.67 | 9.67 |
PV UFCF | ||||||||||
SUM PV UFCF | -2.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -2 | |||||||||
Net Debt | -139 | |||||||||
Equity Value | 136 | |||||||||
Diluted Shares Outstanding, MM | 43 | |||||||||
Equity Value Per Share | 3.17 |
What You Will Get
- Pre-Filled Financial Model: Adicet Bio’s actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
- Instant Calculations: Automatic updates ensure you see results as you make changes.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as clinical trial success rates, R&D expenditures, and market penetration forecasts.
- Instant DCF Analysis: Provides real-time calculations of intrinsic value, net present value, and additional financial metrics.
- High-Precision Valuation: Leverages Adicet Bio's actual financial data for accurate and reliable valuation results.
- Streamlined Scenario Testing: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Avoid the complexities of developing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Adicet Bio, Inc.'s (ACET) pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions.
Why Choose This Calculator for Adicet Bio, Inc. (ACET)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters to suit your specific analysis needs.
- Real-Time Valuation: Monitor immediate changes to Adicet Bio's valuation as you modify inputs.
- Preloaded Data: Comes equipped with Adicet Bio’s latest financial information for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use Adicet Bio, Inc. (ACET)?
- Investors: Make informed decisions with comprehensive insights into cutting-edge therapies.
- Biotech Analysts: Streamline your research with detailed reports on innovative drug development.
- Consultants: Tailor presentations or reports efficiently using our extensive market analysis.
- Healthcare Enthusiasts: Enhance your knowledge of biotechnology advancements through real-case studies.
- Educators and Students: Utilize it as a valuable resource in life sciences and biotech education.
What the Template Contains
- Pre-Filled Data: Includes Adicet Bio, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Adicet Bio, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.